Simone P. Sittig
YOU?
Author Swipe
View article: Supplementary Table and Figure Legends from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines
Supplementary Table and Figure Legends from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines Open
Legends for Supplementary Tables S1-S2 and Supplementary Figures S1-S12.
View article: Supplementary Dataset S1 from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines
Supplementary Dataset S1 from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines Open
The detailed composition of all gene sets used in GSEA.
View article: Supplementary Table S1 from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines
Supplementary Table S1 from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines Open
A list of all molecules detected by antibody microarray (Multiplex analysis) with their UniPort entry name.
View article: Supplementary Table S2 from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines
Supplementary Table S2 from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines Open
GSEA raw data generated by Bubble GUM software.
View article: Supplementary Table S1 from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines
Supplementary Table S1 from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines Open
A list of all molecules detected by antibody microarray (Multiplex analysis) with their UniPort entry name.
View article: Supplementary Table S2 from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines
Supplementary Table S2 from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines Open
GSEA raw data generated by Bubble GUM software.
View article: Supplementary Figures S1-S12 from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines
Supplementary Figures S1-S12 from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines Open
The gating strategy applied to isolate and determine the frequency of BDCA1+ DCs, BDCA1+ CD14+ cells, monocytes and MDSCs from PBMCS of melanoma patients or healthy donors by FACS (S1); The distribution of potentially "missed genes" over t…
View article: Supplementary Dataset S1 from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines
Supplementary Dataset S1 from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines Open
The detailed composition of all gene sets used in GSEA.
View article: Supplementary Figures S1-S12 from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines
Supplementary Figures S1-S12 from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines Open
The gating strategy applied to isolate and determine the frequency of BDCA1+ DCs, BDCA1+ CD14+ cells, monocytes and MDSCs from PBMCS of melanoma patients or healthy donors by FACS (S1); The distribution of potentially "missed genes" over t…
View article: Supplementary Table and Figure Legends from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines
Supplementary Table and Figure Legends from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines Open
Legends for Supplementary Tables S1-S2 and Supplementary Figures S1-S12.
View article: Data from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines
Data from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines Open
The tumor microenvironment is characterized by regulatory T cells, type II macrophages, myeloid-derived suppressor cells, and other immunosuppressive cells that promote malignant progression. Here we report the identification of a novel BD…
View article: Data from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines
Data from Expansion of a BDCA1<sup>+</sup>CD14<sup>+</sup> Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines Open
The tumor microenvironment is characterized by regulatory T cells, type II macrophages, myeloid-derived suppressor cells, and other immunosuppressive cells that promote malignant progression. Here we report the identification of a novel BD…
View article: Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3‐dioxygenase 1 with functional effects on T cell priming
Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3‐dioxygenase 1 with functional effects on T cell priming Open
Dendritic cells (DCs) are key regulators of the immune system that shape T cell responses. Regulation of T cell induction by DCs may occur via the intracellular enzyme indoleamine 2,3‐dioxygenase 1 (IDO), which catalyzes conversion of the …
View article: Author response for "Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3‐dioxygenase 1 with functional effects on T cell priming"
Author response for "Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3‐dioxygenase 1 with functional effects on T cell priming" Open
View article: Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells
Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells Open
View article: Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines
Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines Open
The tumor microenvironment is characterized by regulatory T cells, type II macrophages, myeloid-derived suppressor cells, and other immunosuppressive cells that promote malignant progression. Here we report the identification of a novel BD…
View article: Lipid peroxidation causes endosomal antigen release for cross-presentation
Lipid peroxidation causes endosomal antigen release for cross-presentation Open
View article: Human blood dendritic cell subsets - pinpointing the most potent subset for dendritic cell- based cancer immunotherapy
Human blood dendritic cell subsets - pinpointing the most potent subset for dendritic cell- based cancer immunotherapy Open
View article: Primary Human Blood Dendritic Cells for Cancer Immunotherapy—Tailoring the Immune Response by Dendritic Cell Maturation
Primary Human Blood Dendritic Cells for Cancer Immunotherapy—Tailoring the Immune Response by Dendritic Cell Maturation Open
Dendritic cell (DC)-based cancer vaccines hold the great promise of tipping the balance from tolerance of the tumor to rejection. In the last two decades, we have gained tremendous knowledge about DC-based cancer vaccines. The maturation o…
View article: Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets
Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets Open